Nasdaq
$1.33▲ 0.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $122.8MShares out 92.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
42- 4d agoAfter-hours26.10.21 05:168-KKey event#●●●#●●●
ANAVEX LIFE SCIENCES CORP.Bullish
Anavex Life Sciences has completed the clinical conduct of ADME and DDI pharmacology studies for blarcamesine (ANAVEX 2-73). Additionally, the company received FDA clearance for its Investigational New Drug (IND) application for Fragile X syndrome and is scheduled to meet with the FDA in November to discuss adding pediatric participants to its Phase 3 Rett syndrome study.…more
$1.33+0.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:188-KKey event
ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences has received FDA clearance for its Investigational New Drug (IND) application for blarcamesine to treat Fragile X syndrome. With this approval, the company now has active INDs for all three of its core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company plans to initiate a Phase 2a clinical study involving approximately 60 adult males with Fragile X syndrome.…more
$1.33+0.38%vs prev closeView filingShare - 10.5After-hours26.10.06 06:003Ownership
ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences Corp. has filed a Form 3, disclosing the initial beneficial ownership of securities by newly appointed director Adrian Senderowicz. This filing serves as the official notification of the director's equity holdings in the company.…more
$1.33+0.38%vs prev closeView filingShare
41 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoAfter-hours26.10.21 05:04#●●●#●●●#●●●
Anavex Advances Blarcamesine Clinical Trials and Receives FDA IND Clearance…more
Anavex Life Sciences has completed clinical trials for drug-drug interaction and ADME studies while receiving FDA clearance for its IND application in Fragile X syndrome. The company is also set to meet with the FDA to discuss expanding its Phase 3 Rett syndrome trial to include pediatric participants.…more
$1.33+0.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoAfter-hours26.10.21 05:00
●●●●●●●● ●●●●● ●●●●●●
Anavex has completed clinical pharmacology studies for its lead candidate, blarcamesine, and received FDA clearance for its Fragile X syndrome program. While these milestones mark progress in the clinical pipeline, the company has yet to demonstrate commercial revenue generation.…more
$1.33+0.38%vs prev close - 10.15After-hours26.10.16 05:00
●●●●●●●● ●●●●● ●●●●●●
Anavex Life Sciences has received FDA clearance for its IND application to initiate a Phase 2a clinical trial of blarcamesine for Fragile X syndrome. This milestone completes the company's open IND status across its three core indications, including Alzheimer's and Rett syndrome.…more
$1.33+0.38%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report